Cited by 622Lipoproteins and Cardiovascular HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Goldberg, Anne C., Hopkins, Paul N., Toth, Peter P., Ballantyne, Christie M., Rader, Daniel J., Robinson, Jennifer G., Daniels, Stephen R., Gidding, Samuel S., de Ferranti, Sarah D., Ito, Matthew K., McGowan, Mary P., Moriarty, Patrick M., Cromwell, William C., Ross, Joyce L., Ziajka, Paul E.·2011·Journal of clinical lipidology

DOI 10.1016/j.jacl.2011.03.001

Open this paper in CoChat — free account

Abstract

The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease. FH is among the most commonly occurring congenital metabolic disorders. FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated, particularly among children. Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD.

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2011.03.001

Cites

163 of 163 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Association between Multiple Cardiovascular Risk Factors and Atherosclerosis in Children and Young Adults
Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., & Wattigney, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382302 · Cited by 4,032
The Metabolic Syndrome and Cardiovascular Risk
Mottillo, S., Filion, K. B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E. L., & Eisenberg, M. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.034 · Cited by 3,009
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837

Flagged first, then by citations

Show all 163 references

Sorted by citations

Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Heart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia
Khera, A. V., Won, H.-H., Peloso, G. M., Lawson, K. S., Bartz, T. M., Deng, X., van Leeuwen, E. M., Natarajan, P., Emdin, C. A., Bick, A. G., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.520 · Cited by 942
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv157 · Cited by 891
Self-citation
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association
Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H. T. T., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 586
National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 469
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.519 · Cited by 459
Effects of aerobic exercise on lipids and lipoproteins
Wang, Y., & Xu, D. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0515-5 · Cited by 436
Genetic identification of familial hypercholesterolemia within a single U.S. health care system
Abul-Husn, N. S., Manickam, K., Jones, L. K., Wright, E. A., Hartzel, D. N., Gonzaga-Jauregui, C., O’Dushlaine, C., Leader, J. B., Lester Kirchner, H., Lindbuchler, D. M., et al. (2016) · Science · doi:10.1126/science.aaf7000 · Cited by 425
Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force
Kirkpatrick, C. F., Bolick, J. P., Kris-Etherton, P. M., Sikand, G., Aspry, K. E., Soffer, D. E., Willard, K.-E., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.08.003 · Cited by 390
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Lloyd‐Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M., Orringer, C. E., & Smith, S. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.745 · Cited by 398
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
Watts, G. F., Gidding, S. S., Wierzbicki, A. S., Toth, P. P., Rodrigo Alonso, K., Brown, W. V., Bruckert, É., Defesche, J. C., Lin, K. K., Livingston, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.11.025 · Cited by 384
Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
Raal, F. J., & Santos, R. D. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.019 · Cited by 349
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Child–Parent Familial Hypercholesterolemia Screening in Primary Care
Wald, D. S., Bestwick, J. P., Morris, J. K., Whyte, K., Jenkins, L., & Wald, N. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602777 · Cited by 320
Lymphatic Vessels Are Essential for the Removal of Cholesterol from Peripheral Tissues by SR-BI-Mediated Transport of HDL
Lim, H. Y., Thiam, C. H., Yeo, K. P., Bisoendial, R. J., Hii, C. S., McGrath, K. C. Y., Tan, K. W., Heather, A. K., Alexander, J. S., & Angeli, V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.002 · Cited by 309
Regulation of glucose and lipid metabolism in health and disease
Chen, L., Chen, X., Huang, X., Song, B., Wang, Y., & Wang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-1563-3 · Cited by 313
Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
McGowan, M. P., Dehkordi, S. H. H., Moriarty, P. M., & Duell, P. B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013225 · Cited by 293
Statins for children with familial hypercholesterolemia
Vuorio, A. F., Kuoppala, J., Kovanen, P. T., Humphries, S. E., Tonstad, S., Wiegman, A., Drogari, E., & Ramaswami, U. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006401.pub4 · Cited by 264
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Jazi, M. S., Mohammadi, S., Nikoo, H. R., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 271
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia
Community, R. O. T. G. F. H., Wilemon, K. A., Patel, J. D., Aguilar-Salinas, C. A., Ahmed, C. D., Al-Khnifsawi, M., Almahmeed, W. A., Rodrigo Alonso, K., Al‐Rasadi, K., Badimón, L., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.5173 · Cited by 258
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O’Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 265
Therapeutic nucleic acids: current clinical status
Sridharan, K., & Gogtay, N. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12987 · Cited by 237
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States
deGoma, E. M., Ahmad, Z., O'Brien, E. C., Kindt, I., Shrader, P., Newman, C. B., Pokharel, Y., Baum, S. J., Hemphill, L., Hudgins, L. C., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001381 · Cited by 225
Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries
Futema, M., Shah, S., Cooper, J. A., Li, K., Whittall, R. A., Sharifi, M., Goldberg, O., Drogari, E., Mollaki, V., Wiegman, A., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.231365 · Cited by 213
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Ginsberg, H. N., Rader, D. J., Raal, F. J., Guyton, J. R., Baccara‐Dinet, M. T., Lorenzato, C., Pordy, R. C., & Stroes, E. S. G. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6685-y · Cited by 216
Familial hypercholesterolaemia: A model of care for Australasia
Watts, G. F., SULLIVAN, D. R., Poplawski, N. K., van Bockxmeer, F., Hamilton‐Craig, I. R., Clifton, P. M., O’Brien, R. C., Bishop, W., George, P. M., Barter, P. J., et al. (2011) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2011.06.001 · Cited by 206
Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening
Singh, S., & Bittner, V. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0482-5 · Cited by 206
Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature
Roberts, M. C., Dotson, W. D., DeVore, C., Bednar, E. M., Bowen, D. J., Ganiats, T. G., Green, R. F., Hurst, G. M., Philp, A. R., Ricker, C. N., et al. (2018) · Health Affairs · doi:10.1377/hlthaff.2017.1630 · Cited by 189
The Severe Hypercholesterolemia Phenotype
Sniderman, A. D., Tsimikas, S., & Fazio, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.060 · Cited by 180
PCSK9 Biology and Its Role in Atherothrombosis
Barale, C., Melchionda, E., Morotti, A., & Russo, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115880 · Cited by 180
Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation
Watts, G. F., Gidding, S. S., Wierzbicki, A. S., Toth, P. P., Rodrigo Alonso, K., Brown, W. V., Bruckert, É., Defesche, J. C., Lin, K. K., Livingston, M., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.01.002 · Cited by 165
Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999–2014)
Bucholz, E. M., Rodday, A. M., Kolor, K., Khoury, M. J., & de Ferranti, S. D. (2018) · Circulation · doi:10.1161/circulationaha.117.032321 · Cited by 157
Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
Geary, R. S., Baker, B. F., & Crooke, S. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0224-4 · Cited by 165
The genetics and screening of familial hypercholesterolaemia
Henderson, R., O’Kane, M., McGilligan, V., & Watterson, S. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0256-1 · Cited by 166
Barriers and facilitators for cascade testing in genetic conditions: a systematic review
Srinivasan, S., Won, N. Y., Dotson, W. D., Wright, S. T., & Roberts, M. C. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-00725-5 · Cited by 167
Universal Screening for Familial Hypercholesterolemia in Children
Klančar, G., Grošelj, U., Kovač, J., Bratanič, N., Bratina, N., Podkrajšek, K. T., & Battelino, T. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.017 · Cited by 152
Clinical outcomes of a genomic screening program for actionable genetic conditions
Buchanan, A. H., Lester Kirchner, H., Schwartz, M. L. B., Kelly, M. A., Schmidlen, T., Jones, L. K., Hallquist, M. L. G., Rocha, H., Betts, M., Schwiter, R., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0876-4 · Cited by 143
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group
Wilson, P. W. F., Jacobson, T. A., Martin, S. S., Jackson, E. J., Le, N., Davidson, M. H., Vesper, H. W., Frikke‐Schmidt, R., Ballantyne, C. M., & Remaley, A. T. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.09.046 · Cited by 134
National lipid association annual summary of clinical lipidology 2016
Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128
Lipoprotein apheresis to treat elevated lipoprotein (a)
Waldmann, E., & Parhofer, K. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r056549 · Cited by 131
Update on the molecular biology of dyslipidemias
Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 131
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
Kirkpatrick, C. F., Sikand, G., Petersen, K. S., Anderson, C. A. M., Aspry, K. E., Bolick, J. P., Kris‐Etherton, P. M., & Maki, K. C. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.099 · Cited by 137
Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review
Grošelj, U., Kovač, J., Šuštar, U., Mlinarič, M., Fras, Z., Podkrajšek, K. T., & Battelino, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.858 · Cited by 123
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities
Vuorio, A. F., Watts, G. F., Schneider, W. J., Tsimikas, S., & Kovanen, P. T. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12981 · Cited by 122
The Effects of Exercise Training on the Traditional Lipid Profile and Beyond
Gordon, B., Chen, S., & Durstine, J. L. (2014) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000073 · Cited by 143
Analysis of Differentially Expressed Genes and Molecular Pathways in Familial Hypercholesterolemia Involved in Atherosclerosis: A Systematic and Bioinformatics Approach
Kumar, S. U., Kumar, D. T., Bithia, R., Sankar, S., Magesh, R., Sidenna, M., Doss, C. G. P., & Zayed, H. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00734 · Cited by 114
Genetic Testing for Heritable Cardiovascular Diseases in Pediatric Patients: A Scientific Statement From the American Heart Association
Landstrom, A. P., Kim, J. J., Gelb, B. D., Helm, B. M., Kannankeril, P. J., Semsarian, C., Sturm, A. C., Tristani‐Firouzi, M., & Ware, S. M. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000086 · Cited by 113
Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Robinson, J. G. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.2.139 · Cited by 112
Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia
Genest, J. J., Hegele, R. A., Bergeron, J., Brophy, J. M., Carpentier, A. C., Couture, P., Davignon, J., Dufour, R., Frohlich, J. J., Gaudet, D., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.09.028 · Cited by 110
Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
Wang, A., Richhariya, A., Gandra, S. R., Calimlim, B., Kim, L., Quek, R. G. W., Nordyke, R. J., & Toth, P. P. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003294 · Cited by 110
“To better meet these unmet needs, multiple groups advocate the use of cascade screening.(29)”
Background
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
Kastelein, J. J. P., Robinson, J. G., Farnier, M., Krempf, M., Langslet, G., Lorenzato, C., Gipe, D. A., & Baccara‐Dinet, M. T. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6523-z · Cited by 102
Rapid identification of familial hypercholesterolemia from electronic health records: The SEARCH study
Safarova, M. S., Liu, H., & Kullo, I. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.001 · Cited by 102
Cardiovascular Risk and Statin Therapy Considerations in Women
Gheorghe, G., Toth, P. P., BUNGAU, S. G., Behl, T., Ilie, M., Stoian, A. P., Bratu, O. G., Bacalbaşa, N., Rus, M., & Diaconu, C. C. (2020) · Diagnostics · doi:10.3390/diagnostics10070483 · Cited by 106
Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia
Watts, G. F., SULLIVAN, D. R., Hare, D. L., Kostner, K., Horton, A., Bell, D. A., Brett, T., Trent, R. J., Poplawski, N. K., Martin, A. C., et al. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.943 · Cited by 103
Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics
Scharner, J., & Aznarez, I. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.022 · Cited by 96
Postnuclear disaster evacuation and chronic health in adults in Fukushima, Japan: a long-term retrospective analysis
Nomura, S., Blangiardo, M., Tsubokura, M., Ozaki, A., Morita, T., & Hodgson, S. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010080 · Cited by 96
Coronary Heart Disease Risk Factors in College Students
Arts, J., Fernández, M. L., & Lofgren, I. E. (2014) · Advances in Nutrition · doi:10.3945/an.113.005447 · Cited by 97
Familial hypercholesterolemia: A review
Varghese, M. J. (2014) · Annals of Pediatric Cardiology · doi:10.4103/0974-2069.132478 · Cited by 98
“108 Annals of Pediatric Cardiology 2014 Vol 7 Issue 2 central role in the pathogenesis of FH; one, a defective apo-B100 component of LDL, known as familial defective apoB-100 (clinically indistinguishable from heterozygous LDLR mutations).[11-13] Secondly, a gain of function mutation affecting proprotein convertase su…”
Influential
Statin treatment of children with familial hypercholesterolemia – Trying to balance incomplete evidence of long-term safety and clinical accountability: Are we approaching a consensus?
Vuorio, A. F., Docherty, K. F., Humphries, S. E., Kuoppala, J., & Kovanen, P. T. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.10.032 · Cited by 92
“The National Lipid Association Expert Panel in the US suggested in a recent statement that consideration should be given to the introduction of statin treatment at the age of 8 years or older [9].”
Background
Familial defective apolipoprotein B-100: A review
Andersen, L. H., Miserez, A. R., Ahmad, Z., & Andersen, R. L. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.009 · Cited by 91
Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction
Brænne, I., Kleinecke, M., Reiz, B., Graf, E., Strom, T. M., Wieland, T., Fischer, M., Kessler, T., Hengstenberg, C., Meitinger, T., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.100 · Cited by 94
ApoE knockout rabbits: A novel model for the study of human hyperlipidemia
Niimi, M., Yang, D., Kitajima, S., Ning, B., Wang, C., Shen, L., Liu, E., Zhang, J., Chen, Y. E., & Fan, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.002 · Cited by 88
PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers
Baum, S. J., Toth, P. P., Underberg, J. A., Jellinger, P., Ross, J., & Wilemon, K. (2017) · Clinical Cardiology · doi:10.1002/clc.22713 · Cited by 88
Self-citation
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
Watts, G. F., Gidding, S. S., Wierzbicki, A. S., Toth, P. P., Rodrigo Alonso, K., Brown, W. V., Bruckert, É., Defesche, J. C., Lin, K. K., Livingston, M., et al. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314533218 · Cited by 87
Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels
Bianconi, V., Banach, M., & Pirro, M. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.03.004 · Cited by 85
“[3] Goldgberg AC , Hopkins PN , Toth PP , Ballantyne CM , Rader DJ , Robinson JG , et al.”
Background
Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry
O'Brien, E. C., Roe, M. T., Fraulo, E. S., Peterson, E. D., Ballantyne, C. M., Genest, J. J., Gidding, S. S., Hammond, E., Hemphill, L., Hudgins, L. C., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.12.008 · Cited by 84
Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit
Pang, J., Poulter, E. B., Bell, D. A., Bates, T. R., Jefferson, V.-L., Hillis, G. S., Schultz, C. J., & Watts, G. F. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.07.005 · Cited by 84
Current Role of Lipoprotein Apheresis
Thompson, G. R., & Parhofer, K. G. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0787-5 · Cited by 84
Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia
Kusters, D. M., Caceres, M., Mauricio Coll, B., Cuffie, C. A., Gagné, C., Jacobson, M. S., Kwiterovich, P. O., Lee, R., Lowe, R. S., Massaad, R., et al. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.02.043 · Cited by 82
Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies
Feldman, F., Koudoufio, M., Desjardins, Y., Spahis, S., DELVIN, E. E., & Levy, E. H. (2021) · Nutrients · doi:10.3390/nu13020672 · Cited by 82
National Lipid Association Annual Summary of Clinical Lipidology 2015
Bays, H. E., Jones, P. H., Brown, W. V., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.002 · Cited by 82
Cascade Screening for Familial Hypercholesterolemia (FH)
Ned, R. M., & Sijbrands, E. J. G. (2011) · PLoS Currents · doi:10.1371/currents.rrn1238 · Cited by 81
New Case Detection by Cascade Testing in Familial Hypercholesterolemia
Lee, C., Rivera-Valerio, M., Bangash, H., Prokop, L., & Kullo, I. J. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002723 · Cited by 79
Update on Screening, Etiology, and Treatment of Dyslipidemia in Children
Bamba, V. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3860 · Cited by 80
Management of Cardiovascular Risk: The Importance of Meeting Lipid Targets
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.002 · Cited by 76
ADIPS 2020 guideline for pre‐existing diabetes and pregnancy
Rudland, V. L., Price, S., Hughes, R. C. E., Barrett, H. L., Lagstrom, J., Porter, C., Britten, F. L., Glastras, S. J., Fulcher, I., Wein, P., et al. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13265 · Cited by 85
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry
Ahmad, Z., Andersen, R. L., Andersen, L. H., O'Brien, E. C., Kindt, I., Shrader, P., Vasandani, C., Newman, C. B., deGoma, E. M., Baum, S. J., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.07.011 · Cited by 78
A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia
Ademi, Z., Watts, G. F., Juniper, A., & Liew, D. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.280 · Cited by 76
Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia
Solanas-Barca, M., de Castro-Orós, I., Mateo-Gallego, R., Cofán, M., Plana, N., Puzo, J., Burillo, E., Martín-Fuentes, P., Ros, E., Masana, L., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.03.011 · Cited by 74
Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience
Bell, D. A., Pang, J., Burrows, S., Bates, T. R., BOCKXMEER, F. M. V., Hooper, A. J., O'Leary, P. C., Burnett, J. R., & Watts, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.036 · Cited by 74
Familial Hypercholesterolemia
Klose, G., Laufs, U., März, W., & Windler, E. E. T. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0523 · Cited by 73
Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia
Futema, M., Bourbon, M., Williams, M., & Humphries, S. E. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.006 · Cited by 76
Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia
Malhotra, A., Shafiq, N., Arora, A., Singh, M., Kumar, R., & Malhotra, S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001918.pub3 · Cited by 72
Familial Hypercholesterolemia: An Under‐recognized but Significant Concern in Cardiology Practice
Foody, J. M. (2013) · Clinical Cardiology · doi:10.1002/clc.22223 · Cited by 73
Dyslipidemias
Wójcik, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-04414-9_126 · Cited by 70
I Diretriz Brasileira de Hipercolesterolemia Familiar (HF)
Santos, R., Gagliardi, A., Xavier, H. T., Filho, A. C., Araújo, D., Cesena, F., Alves, R., Pereira, A., Lotemberg, A., Chacra, A., et al. (2012) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20120202 · Cited by 70
Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography
Li, J., Li, S., Zhu, C., Wu, N., Zhang, Y., Guo, Y., Gao, Y., Li, X., Qing, P., Cui, C.-J., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308456 · Cited by 69
Familial Hypercholesterolaemia Diagnosis and Management
Rodrigo Alonso, K., de Isla, L. P., Muñiz-Grijalvo, O., Díaz-Díaz, J. L., & Mata, P. (2018) · European Cardiology Review · doi:10.15420/ecr.2018:10:2 · Cited by 72
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
Ramaswami, U., Futema, M., Bogsrud, M. P., Holven, K. B., van Lennep, J. E. R., Wiegman, A., Descamps, O. S., Vrablı́k, M., Freiberger, T., Dieplinger, H., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.11.012 · Cited by 69
Review of Clinical Practice Guidelines for the Management of LDL-Related Risk
Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Dunn, S. P., & Urbina, E. M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.015 · Cited by 69
DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG)
Murray, M. F., Giovanni, M. A., Doyle, D. L., Harrison, S. M., Lyon, E., Manickam, K., Monaghan, K. G., Rasmussen, S. A., Scheuner, M. T., Palomaki, G. E., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-020-01082-w · Cited by 72
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia
Arai, K., Orsoni, A., Mallat, Z., Tedgui, A., Witztum, J. L., Bruckert, É., Tselepis, A. D., Chapman, M. J., & Tsimikas, S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p027235 · Cited by 67
Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia
Pérez‐Calahorra, S., Laclaustra, M., Marco-Benedí, V., Lamíquiz-Moneo, I., Pedro‐Botet, J., Plana, N., Sánchez-Hernández, R. M., Amor, A. J., Almagro, F., Fuentes, F. J., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.003 · Cited by 69

Authors: Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., McGowan, M. P., Moriarty, P. M., Cromwell, W. C., Ross, J. L., & Ziajka, P. E.
Affiliations: Washington University in St. Louis (US)
University of Utah (US)
CGH Medical Center (US)
Baylor College of Medicine (US)
University of Pennsylvania (US)
University of Iowa (US)
Children's Hospital Colorado (US)
Alfred I. duPont Hospital for Children (US)
Oregon State University (US)
Concord Hospital (US)
University of Kansas Medical Center (US)
Wake Forest University (US)
University of Pennsylvania Health System (US)
Corresponding author: Goldberg, Anne C.
ORCID: Goldberg, Anne C.
Hopkins, Paul N.
Toth, Peter P.
Ballantyne, Christie M.
Rader, Daniel J.
Robinson, Jennifer G.
Daniels, Stephen R.
Gidding, Samuel S.
McGowan, Mary P.
Moriarty, Patrick M.
Cromwell, William C.
Venue: Journal of clinical lipidology
Publisher: Elsevier BV
Published: 2011-05
Volume: 5
Issue: 3
Pages: 133-140
ISSN: 1876-4789 (ISSN-L)
1933-2874
DOI: 10.1016/j.jacl.2011.03.001
OpenAlex: W2943032204
Cited by: 622
References: 163
Citations by year: 2026: 13 · 2025: 16 · 2024: 15 · 2023: 22 · 2022: 23 · 2021: 55 · 2020: 53 · 2019: 39 · 2018: 63 · 2017: 47 · 2016: 76 · 2015: 58 · 2014: 56 · 2013: 47 · 2012: 28
FWCI: 45.77
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of clinical lipidology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: familial hypercholesterolemia, screening, diagnosis, lipid-lowering therapy, LDL cholesterol lowering, coronary heart disease risk, pediatric patients, underdiagnosis, primary care, genetic lipid disorders
MeSH terms: Proprotein Convertase 9, Adult, Anticholesteremic Agents, Apolipoproteins B, Child, Coronary Disease, Genetic Testing, Homozygote, Humans, Hyperlipoproteinemia Type II, Mutation, Serine Endopeptidases, Practice Guidelines as Topic, LDL-Receptor Related Proteins, Proprotein Convertases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks